These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15487810)

  • 1. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
    Reyderman L; Kosoglou T; Statkevich P; Pember L; Boutros T; Maxwell SE; Affrime M; Batra V
    Int J Clin Pharmacol Ther; 2004 Sep; 42(9):512-8. PubMed ID: 15487810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers.
    Reyderman L; Kosoglou T; Boutros T; Seiberling M; Statkevich P
    Curr Med Res Opin; 2004 Sep; 20(9):1493-500. PubMed ID: 15383199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
    Kosoglou T; Statkevich P; Johnson-Levonas AO; Paolini JF; Bergman AJ; Alton KB
    Clin Pharmacokinet; 2005; 44(5):467-94. PubMed ID: 15871634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.
    Migoya EM; Bergman A; Hreniuk D; Matthews N; Yi B; Roadcap B; Valesky R; Liu L; Riffel K; Groff M; Zhao JJ; Musson DG; Gambale J; Kosoglou T; Statkevich P; Lasseter KC; Laurent A; Johnson-Levonas AO; Murphy G; Gottesdiener K; Paolini JF
    Int J Clin Pharmacol Ther; 2006 Feb; 44(2):83-92. PubMed ID: 16502768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.
    Kosoglou T; Meyer I; Veltri EP; Statkevich P; Yang B; Zhu Y; Mellars L; Maxwell SE; Patrick JE; Cutler DL; Batra VK; Affrime MB
    Br J Clin Pharmacol; 2002 Sep; 54(3):309-19. PubMed ID: 12236852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
    Jackson A; D'Avolio A; Watson V; Bonora S; Back D; Taylor J; Armenis K; Gazzard B; Moyle G; Boffito M
    J Antimicrob Chemother; 2011 Apr; 66(4):885-9. PubMed ID: 21393207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin.
    Kosoglou T; Statkevich P; Meyer I; Cutler DL; Musiol B; Yang B; Zhu Y; Maxwell SE; Veltri EP
    Curr Med Res Opin; 2004 Jun; 20(6):955-65. PubMed ID: 15200755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
    Reyderman L; Kosoglou T; Cutler DL; Maxwell S; Statkevich P
    Curr Med Res Opin; 2005 Aug; 21(8):1171-9. PubMed ID: 16083526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
    Yu RZ; Geary RS; Flaim JD; Riley GC; Tribble DL; vanVliet AA; Wedel MK
    Clin Pharmacokinet; 2009; 48(1):39-50. PubMed ID: 19071883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
    Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
    Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
    Gustavson LE; Schweitzer SM; Burt DA; Achari R; Rieser MJ; Edeki T; Chira T; Yannicelli HD; Kelly MT
    Clin Ther; 2006 Mar; 28(3):373-87. PubMed ID: 16750452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.
    Patrick JE; Kosoglou T; Stauber KL; Alton KB; Maxwell SE; Zhu Y; Statkevich P; Iannucci R; Chowdhury S; Affrime M; Cayen MN
    Drug Metab Dispos; 2002 Apr; 30(4):430-7. PubMed ID: 11901097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
    Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
    Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
    Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.
    Derks M; Abt M; Phelan M
    Br J Clin Pharmacol; 2010 Dec; 70(6):825-33. PubMed ID: 21175438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
    Kosoglou T; Zhu Y; Statkevich P; Triantafyllou I; Taggart W; Xuan F; Kim KT; Cutler DL
    Eur J Clin Pharmacol; 2011 May; 67(5):483-92. PubMed ID: 21120461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects.
    Chu NN; Chen WL; Xu HR; Li XN
    Clin Drug Investig; 2012 Dec; 32(12):791-8. PubMed ID: 23109219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.